Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 3:11:1401.
doi: 10.3389/fmicb.2020.01401. eCollection 2020.

Prevalence and Antifungal Susceptibility of Pathogenic Yeasts in China: A 10-Year Retrospective Study in a Teaching Hospital

Affiliations

Prevalence and Antifungal Susceptibility of Pathogenic Yeasts in China: A 10-Year Retrospective Study in a Teaching Hospital

Yinggai Song et al. Front Microbiol. .

Abstract

To determine the dynamic changes of pathogenic yeast prevalence and antifungal susceptibility patterns in tertiary hospitals in China, we analyzed 527 yeast isolates preserved in the Research Center for Medical Mycology at Peking University, Beijing, China, between Jan 2010 and Dec 2019 and correctly identified 19 yeast species by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and ribosomal DNA sequencing. Antifungal susceptibility testing was performed following a Sensititre YeastOne colorimetric microdilution panel with nine clinically available antifungals. The Clinical and Laboratory Standards Institute (CLSI)-approved standard M27-A3 (S4) and newly revised clinical breakpoints or species-specific and method-specific epidemiological cutoff values were used for the interpretation of susceptibility test data. In this study, although Candida albicans was the predominant single species, non-C. albicans species constituted >50% of isolates in 6 out of 10 years, and more rare species were present in the recent 5 years. The non-C. albicans species identified most frequently were Candida parapsilosis sensu stricto, Candida tropicalis, and Candida glabrata. The prevalence of fluconazole and voriconazole resistance in the C. parapsilosis sensu stricto population was <3%, but C. tropicalis exhibited decreased susceptibility to fluconazole (42, 57.5%) and voriconazole (31, 42.5%), and 22 (30.1%) C. tropicalis isolates exhibited wild-type minimum inhibitory concentrations (MICs) to posaconazole. Furthermore, fluconazole and voriconazole cross-resistance prevalence in C. tropicalis was 19 (26.1%). The overall prevalence of fluconazole resistance in the C. glabrata population was 14 (26.9%), and prevalence of isolates exhibiting voriconazole non-wild-type MICs was 33 (63.5%). High-level echinocandin resistance was mainly observed in C. glabrata, and the prevalence rates of isolate resistance to anidulafungin, micafungin, and caspofungin were 5 (9.6%), 5 (9.6%), and 4 (7.7%), respectively. Moreover, one C. glabrata isolate showed multidrug resistant to azoles, echinocandins, and flucytosine. Overall, the 10-year surveillance study showed the increasing prevalence of non-C. albicans species over time; the emergence of azole resistance in C. tropicalis and multidrug resistance in C. glabrata over the years reinforced the need for epidemiological surveillance and monitoring.

Keywords: Candida spp.; Sensititre YeastOne; antifungal susceptibility; candidemia; echinocandins; invasive fungal infection; triazoles; yeast isolate.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Species distribution over 10 years of surveillance. Yeast species varied across years. More rare species were isolated in the recent 5 years; C. albicans was the predominant single species. Non-C. albicans species identified most frequently were C. parapsilosis sensu stricto, C. tropicalis, and C. glabrata.

References

    1. Alexander B. D., Johnson M. D., Pfeiffer C. D., Jiménez-Ortigosa C., Catania J., Booker R., et al. (2013). Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56 1724–1732. 10.1093/cid/cit136 - DOI - PMC - PubMed
    1. Alves J., Palma P., Azevedo D., Rello J. (2018). Candidemia in the patient with malignancy. Hosp. Pract. 46 246–252. 10.1080/21548331.2018.1508290 - DOI - PubMed
    1. Andes D. R., Safdar N., Baddley J. W., Playford G., Reboli A. C., Rex J. H., et al. (2012). Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54 1110–1122. 10.1093/cid/cis021 - DOI - PubMed
    1. Astvad K. M. T., Johansen H. K., Røder B. L., Rosenvinge F. S., Knudsen J. D., Lemming L., et al. (2018). Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern. J. Clin. Microbiol. 56 e1564–e1567. 10.1128/JCM.01564-17 - DOI - PMC - PubMed
    1. Berdal J. E., Haagensen R., Ranheim T., Bjørnholt J. V. (2014). Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital. PLoS One 9:e103916. 10.1371/journal.pone.0103916 - DOI - PMC - PubMed